Alexander Yowei Sheu1, Dingxin Wang1, Johnathan Chung2, Robert K. Ryu2, Reed A. Omary1,3, Debiao Li1, Andrew C. Larson1,3
1Departments of Radiology and Biomedical Engineering, Northwestern University, Chicago, IL, United States; 2Department of Radiology, Northwestern University, Chicago, IL, United States; 3Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, United States
Quantitative DCE-MRI can be used to measure pharmacokinetic parameters (Ktrans, ve, and vp) that indicate tumor angiogenesis and perfusion. The purpose of this study was to develop an innovative hybrid reference tissue calibrated dual-bolus 3D quantitative DCE-MRI method. Tissue contrast enhancement was quantified using 3D GRE DCE-MRI during first-bolus, AIF was monitored using 2D SR GRE DCE-MRI during second-bolus, and reference tissue (back muscle) was used to provide the final calibration. Our results support the use of quantitative DCE-MRI to differentiate hypervascular tumor tissue from the necrotic core, providing valuable diagnostic information about the stage and segmentation of a tumor.